GSK posts Q3 2026 earnings beat, reaffirms guidance but shares slide on vaccine dip and restructuring charge
GlaxoSmithKline reported third‑quarter 2026 revenue of £8.89 billion, up about 5 % year‑on‑year, and core earnings per share of 54.6 pence, beating analyst forecasts. Core operating profit rose 5 % to roughly £3.08 billion, but statutory profit fell 16 % after a £328 million restructuring charge. The company kept its full‑year 2026 turnover and profit guidance and declared a 17 pence dividend, while its share price dropped 4‑5 % on the market.
Why it matters
Investors saw the earnings beat offset by weaker vaccine sales and the restructuring hit, prompting a 4.6 % fall in GSK shares and a sell rating from Barclays. The reaffirmed guidance means the outlook for turnover growth of 3‑5 % and core profit growth of 7‑9 % remains unchanged for the year.
Key facts
- 1Q3 2026 revenue was £8.89 billion, up 5 % year‑on‑year. globalbankingandfinance.com
- 2Core earnings per share were 54.6 pence, above the consensus of 50.4 pence. ksl.com
- 3Core operating profit increased 5 % to £3.08 billion. rttnews.com
- 4Statutory operating profit fell 16 % due to a £328 million restructuring charge. finance.yahoo.com
- 5The company declared a Q3 dividend of 17 pence per share. directorstalkinterviews.com
- 6A £2 billion share buyback programme was completed in Q2 2026. tradingview.com
Summary written by AlphAI AI Desk from 20 of 22 sources. Not investment advice. Figures are as stated by the linked sources.